Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis
Retrophin, based in San Diego, announced that the U.S. Food and Drug Administration (FDA) had given its 100 mg and 300 mg tablets of Thiola EC (tiopronin) the thumbs-up to treat cystinuria. Cystinuria is a rare inherited disease that results in a buildup of cystine levels in the urine, causing the development of recurring cystine kidney stones.
Martin Shkreli may be cooling his heels in a federal prison, but the pharma pricing strategy he pursued that got him into an intense national controversy appears to be alive and well in Europe this week.
A group of Dutch doctors and health advocates are taking action against the Italian pharmaceutical firm Leadiant Biosciences who have increased the price of a lifesaving drug to 500 times its original price.
The high price of pharmaceuticals has become a constant topic of conversation in the U.S. As medical costs rise, consumers face greater financial uncertainty. And day after day, both the White House and Congress make promises that they will lower prescription costs to alleviate constituent concerns, but few changes have backed up their words.
Sigma-tau Arzneimittel GmbH Chenodeoxycholic acid sigma-tau (chenodeoxycholic acid) Receives Approval In Europe
Eleven new medicines have taken a giant leap closer to European Union approval after having won the backing of the Committee for Medicinal Products for Human Use.
Retrophin Inc (NASDAQ:RTRX) was downgraded by research analysts at Vetr from a “strong-buy” rating to a “buy” rating in a report released on Monday, MarketBeat.Com reports. They presently have a $25.00 target price on the biopharmaceutical company’s stock. Vetr‘s price target indicates a potential upside of 11.86% from the company’s current price.
Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today that the Cerilliant® brand within its Applied Diagnostics and Testing business segment has launched its new bile acid reference standards product line with ten certified Snap-N-Spike® solutions of the most routinely tested bile acids and their stable-labeled internal standards. These new solution certified reference materials (CRMs) consist of lithocholic acid, taurocholic acid and native and deuterium-labeled analogs of cholic acid, chenodeoxycholic acid, deoxycholic acid, and ursodeoxycholic acid.
Scientists have been searching for chemicals or conditions that can stimulate the activity of energy-burning brown fat as a potential means of treating obesity. Adult humans, unlike babies and some animals, don’t have too much brown fat to work with, however. Now, researchers in Texas have found that humans—victims of extreme burn trauma, in particular—can actually convert white fat into brown fat, a phenomenon previously witnessed only in animals and in vitro models.